Related references
Note: Only part of the references are listed.Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
C. S. Chim et al.
LEUKEMIA (2018)
Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma
Ujjawal H. Gandhi et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma
Dan T. Vogl et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
NCCN Guidelines (R) Insights Multiple Myeloma, Version 3.2018 Featured Updates to the NCCN Guidelines
Shaji K. Kumar et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Carfilzomib-Associated Cardiovascular Adverse Events A Systematic Review and Meta-analysis
Adam J. Waxman et al.
JAMA ONCOLOGY (2018)
Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma
Nizar J. Bahlis et al.
BLOOD (2018)
Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia
Christine Chen et al.
BLOOD (2018)
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
Meletios A. Dimopoulos et al.
LANCET ONCOLOGY (2017)
Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis
Kellie R. Machlus et al.
BLOOD (2017)
Selinexor (KPT-330) Induces Tumor Suppression through Nuclear Sequestration of IκB and Downregulation of Survivin
Jayasree S. Nair et al.
CLINICAL CANCER RESEARCH (2017)
Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor
Shaun Rosebeck et al.
MOLECULAR CANCER THERAPEUTICS (2016)
CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma
James R. Berenson et al.
BLOOD (2016)
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma
Meletios A. Dimopoulos et al.
BLOOD (2016)
Treatment of relapsed and refractory multiple myeloma
Pieter Sonneveld et al.
HAEMATOLOGICA (2016)
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Meletios A. Dimopoulos et al.
LANCET ONCOLOGY (2016)
Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?
Nishitha Thumallapally et al.
ONCOTARGETS AND THERAPY (2016)
Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death
Trinayan Kashyap et al.
ONCOTARGET (2016)
XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IkBa and overcomes acquired proteasome inhibitor resistance in human multiple myeloma
Joel G. Turner et al.
ONCOTARGET (2016)
Treatment of relapsed and refractory multiple myeloma
Pieter Sonneveld et al.
HAEMATOLOGICA (2016)
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
Jatin J. Shah et al.
BLOOD (2015)
Treatment options for relapsed and refractory multiple myeloma
Ajay K. Nooka et al.
BLOOD (2015)
Molecular Pathways: Anticancer Activity by Inhibition of Nucleocytoplasmic Shuttling
Fabio Conforti et al.
CLINICAL CANCER RESEARCH (2015)
Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma
Jesus G. Berdeja et al.
HAEMATOLOGICA (2015)
Phase I Study of 30-Minute Infusion of Carfilzomib As Single Agent or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Kyriakos P. Papadopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma
Jesus G. Berdeja et al.
HAEMATOLOGICA (2015)
Selective inhibitors of nuclear export (SINE) in hematological malignancies
Arundhati Das et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2015)
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
Paul G. Richardson et al.
BLOOD (2014)
Nucleo-cytoplasmic transport as a therapeutic target of cancer
Giovanni Luca Gravina et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications
Y-T Tai et al.
LEUKEMIA (2014)
Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy
J. R. Berenson et al.
LEUKEMIA (2014)
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib
Paul G. Richardson et al.
BLOOD (2013)
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Jesus San Miguel et al.
LANCET ONCOLOGY (2013)
Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276
J. Schmidt et al.
LEUKEMIA (2013)
The resistance mechanisms of proteasome inhibitor bortezomib
Shuqing Lu et al.
BIOMARKER RESEARCH (2013)
Aphase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
David S. Siegel et al.
BLOOD (2012)
Identification of Molecular Vulnerabilities in Human Multiple Myeloma Cells by RNA Interference Lethality Screening of the Druggable Genome
Rodger E. Tiedemann et al.
CANCER RESEARCH (2012)
The Oncogene eIF4E Reprograms the Nuclear Pore Complex to Promote mRNA Export and Oncogenic Transformation
Biljana Culjkovic-Kraljacic et al.
CELL REPORTS (2012)
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
S. Vincent Rajkumar et al.
BLOOD (2011)
Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010
Hermann Brenner et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Bortezomib-resistant nuclear Factor-κB activity in multiple myeloma cells
Stephanie Markovina et al.
MOLECULAR CANCER RESEARCH (2008)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
Share Paper
